Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology. Its mRNA technology could allow the firm to compete in a wide range of ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Moderna has also filed for approval for a combination Covid-flu shot. And the company anticipates efficacy data this year from late-stage studies of vaccines for seasonal flu and norovirus ...

Moderna's financial challenges are compounded by a slowing adoption of its second product, the RSV vaccine, and an experimental cytomegalovirus (CMV) vaccine that has yet to meet early efficacy ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to ... and will evaluate the efficacy, safety, and immunogenicity of mRNA-1403 across two seasons.